WO2009013563A3 - Use of lipid conjugates in the treatment of diseases or disorders of the eye - Google Patents

Use of lipid conjugates in the treatment of diseases or disorders of the eye Download PDF

Info

Publication number
WO2009013563A3
WO2009013563A3 PCT/IB2007/004668 IB2007004668W WO2009013563A3 WO 2009013563 A3 WO2009013563 A3 WO 2009013563A3 IB 2007004668 W IB2007004668 W IB 2007004668W WO 2009013563 A3 WO2009013563 A3 WO 2009013563A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
eye
disorders
diseases
dimer
Prior art date
Application number
PCT/IB2007/004668
Other languages
French (fr)
Other versions
WO2009013563A2 (en
Inventor
Saul Yedgar
Yuval Cohen
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem
Morria Biopharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem, Morria Biopharmaceuticals Inc. filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem
Publication of WO2009013563A2 publication Critical patent/WO2009013563A2/en
Publication of WO2009013563A3 publication Critical patent/WO2009013563A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
PCT/IB2007/004668 2006-11-13 2007-11-14 Use of lipid conjugates in the treatment of diseases or disorders of the eye WO2009013563A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85835206P 2006-11-13 2006-11-13
US60/858,352 2006-11-13
US90778507P 2007-04-17 2007-04-17
US60/907,785 2007-04-17

Publications (2)

Publication Number Publication Date
WO2009013563A2 WO2009013563A2 (en) 2009-01-29
WO2009013563A3 true WO2009013563A3 (en) 2013-01-17

Family

ID=40281895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004668 WO2009013563A2 (en) 2006-11-13 2007-11-14 Use of lipid conjugates in the treatment of diseases or disorders of the eye

Country Status (1)

Country Link
WO (1) WO2009013563A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705785A1 (en) * 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
CN113546178A (en) * 2015-12-09 2021-10-26 加利福尼亚大学董事会 Methods of treating ocular diseases or disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079211A1 (en) * 2000-01-10 2005-04-14 Saul Yedgar Use of lipid conjugates in the treatment of diseases of the nervous system
US20060024374A1 (en) * 2002-10-31 2006-02-02 Gasco Maria R Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
US20060189570A1 (en) * 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079211A1 (en) * 2000-01-10 2005-04-14 Saul Yedgar Use of lipid conjugates in the treatment of diseases of the nervous system
US20060189570A1 (en) * 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
US20060024374A1 (en) * 2002-10-31 2006-02-02 Gasco Maria R Pharmaceutical compositions suitable for the treatment of ophthalmic diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUGIU ET AL.: "Identification of Oxidatively Truncated Ethanolamine Phospholipids in Retina and Their Generation from Polyunsaturated Phosphatidylethanolamines", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 19, no. ISS. 2, 4 January 2006 (2006-01-04), pages 262 - 271 *
MASSAGUER ET AL.: "Synthesis of RGD Containing Peptides. Comparative Study of Their Incorporation to the Surface of 5-Fluoruridine Loaded Liposomes", JOURNAL OF LIPOSOME RESEARCH, vol. 11, no. 1, 1 March 2001 (2001-03-01), pages 103 - 113 *

Also Published As

Publication number Publication date
WO2009013563A2 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
WO2008059501A3 (en) Use of lipid conjugates in the treatment of diseases or disorders of the eye
Shah et al. Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy
JP2022525036A (en) Compositions and methods of use containing substances having neuroplastic activity administered in non-psychedelic / psychotic abnormal doses and formulations.
WO2007100745A3 (en) Apparatus and formulations for suprachoroidal drug delivery
BRPI0506983A (en) localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid
WO2010068281A3 (en) Contact lens drug delivery device
US11648261B2 (en) Method of treating, reducing, or alleviating a medical condition in a patient
WO2006119128A8 (en) Vascular targeting of ocular neovascularization
NZ586003A (en) Antigen binding proteins that bind beta-amyloid peptide
WO2005110473A3 (en) Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
JP2008540552A5 (en)
WO2008045330A3 (en) Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure
Zhao et al. An Update on the Routes for the Delivery of Donepezil
WO2009013563A3 (en) Use of lipid conjugates in the treatment of diseases or disorders of the eye
WO2006094027A3 (en) Combination therapy for topical application
WO2006054304A3 (en) Use of lipid conjugates in the treatment of disease
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
Mustfa et al. Nanomedicine approaches to negotiate local biobarriers for topical drug delivery
TWI815423B (en) Methods and pharmaceutical compositions for treating myopia
NZ622403A (en) Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method
EA200970562A1 (en) APPLICATION OF L-CARNITINE FOR THE OBTAINING OF A MEDICINE IN THE FORM OF EYE DROPS FOR THE TREATMENT OF CORNICE DISEASES
WO2010047803A3 (en) A method for the treatment of proliferative disorders of the eye
Mulkutkar et al. Polymeric microneedles for the eye: An overview of advances and ocular applications for minimally invasive drug delivery
Dubey et al. Ocular drug delivery systems for treatment of glaucoma
Montoya-Álvarez et al. Diabetic retinopathy treatments based on nanotechnology

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07875159

Country of ref document: EP

Kind code of ref document: A2